China Gets First Joint-Venture CRO
This article was originally published in PharmAsia News
Executive Summary
Rundo Cronova Clinical Research (Shanghai) Co., China's first joint venture contract research organization venture between Rundo International Clinical Research Co. and Japan's Cronova, was officially established Dec. 19, 2007. Rundo and Cronova hold 65 percent and 35 percent stakes of the new company, respectively. Rundo, a well-known China CRO, focuses on clinical research business with international partners while Cronova is a leading CRO in Japan. Both firms intend to raise their profiles with plans to open up to three subsidiaries or branch offices in China within a year. (Click here for more)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.